1GLOBAL
22.2.2024 18:40:31 CET | Business Wire | Press release
The range of industries adopting 1GLOBAL’s innovative services continues to grow as more than 30 million European customers will be soon avoiding roaming charges in over 160 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222033843/en/
Data Roaming Without Worries, Now in Every App: eSIM Innovator 1GLOBAL gives FinTech its Own Roaming Service. (Graphic: Business Wire)
By fully integrating the 1GLOBAL API, global fintech Revolut now offers its customers simple, fast access to 1GLOBAL's low-cost global mobile network. Once activated by the user, an embedded SIM (eSIM) is generated for the mobile device.
"Without having to leave the Revolut app, users can install an eSIM within one minute,” said Hakan Koç, Founder and CEO of 1GLOBAL. “This is why players from a wide range of industries such as travel, insurance, fintech, airlines, VIP logistics and more are all coming to us to increase the range of services they offer by integrating our connectivity."
Instead of having to obtain a physical SIM to access the local network on arrival, customers using apps that integrate 1GLOBAL’s technology will simply set up an eSIM on their device. This gives them complete control of their connection, including a display of data consumption. They can also use the app to buy a data plan even when they’ve already run out of allowance.
”At Revolut, we know how important it is for our customers that they stay connected to Revolut services, wherever they are, without worrying about their data allowance. Revolut eSIMs, developed in partnership with 1Global, is a convenient technology and provides great value tailored to our global audience," commented David Tirado, Global Business VP at Revolut.
Any company can integrate 1GLOBAL tech into its own customer offering via a suite of APIs. As a result, customers stay within that app for longer, a new revenue channel is created, value for customers is generated and brand loyalty increased.
In Revolut’s case, full integration of 1GLOBAL technology was made into its own app and under its own brand. Alternatively, companies can offer 1GLOBAL connectivity simply as a 3rd party or affiliate via references (such as a QR code) that directs the user to download their eSIM and 1GLOBAL software.
"As a telecommunications technology innovator, we have created our own global telecommunications network and can issue eSIMs and an International Mobile Subscriber Identity (IMSI),” explains Koç. “This distinguishes us from vendors who do not have their own network infrastructure and simply resell data packages.”
The 1GLOBAL platform gives app operators the ability to offer users global connection supported by nine Mobile Virtual Network Operators (MVNO), five international sponsored roaming partners, and over 150 interconnects. This kind of ‘hyperscale’ connectivity, with 2000 routes to 350 mobile carriers spanning 2G to 5G and LPWAN, would be impossible without leveraging 1GLOBAL’s innovative technology.
About 1GLOBAL
1GLOBAL provides quick and secure mobile network connectivity in over 160 countries worldwide. Their eSIM technology integrates seamlessly into the existing Revolut app and can be installed on any eSIM-compatible mobile device in less than a minute.
Founded in 2022, 1GLOBAL is the new startup of Hakan Koç, co-founder and former Co-CEO of AUTO1 Group. 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised, GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and have been granted fully regulated MVNO status in nine of them.
About Revolut
Revolut is a global fintech, helping people get more from their money. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, more than 35 million customers around the world use dozens of Revolut’s innovative products to make more than half a billion transactions a month.
Across our personal and business accounts, we give customers more control over their finances and connect people seamlessly across the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222033843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom